Profile data is unavailable for this security.
About the company
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
- Revenue in USD (TTM)68.62m
- Net income in USD-227.23m
- Incorporated2011
- Employees273.00
- LocationADC Therapeutics SABiopole, route de la Corniche 3BEPALINGES 1066SwitzerlandCHE
- Phone+41 216530200
- Websitehttps://adctherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nautilus Biotechnology Inc | 0.00 | -67.44m | 346.98m | 163.00 | -- | 1.39 | -- | -- | -0.5402 | -0.5402 | 0.00 | 1.99 | 0.00 | -- | -- | 0.00 | -21.26 | -- | -21.85 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.93 | -- | -- | -- |
| Jasper Therapeutics Inc | 0.00 | -63.93m | 348.48m | 45.00 | -- | 3.08 | -- | -- | -5.60 | -5.60 | 0.00 | 7.51 | 0.00 | -- | -- | 0.00 | -48.30 | -- | -51.58 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.06 | -- | -- | -- |
| Fractyl Health Inc | 148.00k | -83.16m | 348.69m | 102.00 | -- | 4.14 | -- | 2,356.01 | -1.73 | -1.73 | 0.0031 | 1.76 | -- | -- | -- | 1,450.98 | -- | -- | -- | -- | 37.16 | -- | -46,270.95 | -- | 9.37 | -5.10 | 0.2542 | -- | -- | -- | -48.15 | -- | -- | -- |
| Zura Bio Ltd | 0.00 | -60.18m | 350.26m | 14.00 | -- | 3.93 | -- | -- | -1.63 | -1.63 | 0.00 | 1.40 | 0.00 | -- | -- | 0.00 | -86.77 | -- | -127.21 | -- | -- | -- | -- | -- | -- | -- | 0.021 | -- | -- | -- | -2,050.99 | -- | -- | -- |
| Precigen Inc | 5.44m | -96.91m | 350.86m | 202.00 | -- | 3.59 | -- | 64.51 | -0.3896 | -0.3896 | 0.0219 | 0.3877 | 0.0289 | -- | 4.12 | 26,925.74 | -51.49 | -31.50 | -64.42 | -38.63 | -4.19 | 44.00 | -1,781.73 | -232.32 | -- | -- | 0.00 | -- | -76.87 | -47.16 | -20.22 | -- | -48.30 | -- |
| MeiraGTx Holdings PLC | 11.38m | -74.11m | 353.69m | 402.00 | -- | 2.91 | -- | 31.08 | -1.27 | -1.27 | 0.1887 | 1.89 | 0.0381 | -- | 0.4821 | 27,159.90 | -24.81 | -26.40 | -31.62 | -32.66 | -- | -- | -651.19 | -420.70 | -- | -27.54 | 0.3729 | -- | -11.95 | -- | 35.17 | -- | 12.37 | -- |
| ADC Therapeutics SA | 68.62m | -227.23m | 358.79m | 273.00 | -- | -- | -- | 5.23 | -2.77 | -2.77 | 0.8368 | -2.35 | 0.1769 | 0.2683 | 2.91 | 251,351.60 | -56.99 | -48.41 | -69.99 | -55.63 | 93.30 | -- | -322.09 | -308.62 | 4.35 | -4.14 | 1.85 | -- | -66.86 | 127.56 | -52.78 | -- | 5.42 | -- |
| Q32 Bio Inc | 354.00k | -83.09m | 359.46m | 39.00 | -- | 7.36 | -- | 1,015.42 | -25.73 | -25.73 | 0.1182 | 4.09 | 0.002 | -- | -- | 50,571.43 | -34.17 | -34.98 | -40.05 | -37.92 | -- | -- | -16,901.98 | -971.76 | -- | -- | 0.2039 | -- | -63.97 | -26.32 | -2,156.96 | -- | -60.90 | -- |
| Tourmaline Bio Inc | 0.00 | -32.94m | 359.82m | 44.00 | -- | 1.02 | -- | -- | -5.35 | -5.35 | 0.00 | 13.81 | 0.00 | -- | -- | 0.00 | -12.39 | -- | -12.75 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.99 | -- | -- | -- |
| Fibrobiologics Inc | 0.00 | -22.53m | 359.91m | 10.00 | -- | -- | -- | -- | -1.03 | -1.03 | 0.00 | -0.1181 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -272.15 | -- | -- | -- |
| OraSure Technologies, Inc. | 304.64m | 22.85m | 362.40m | 638.00 | 16.12 | 0.8502 | 8.46 | 1.19 | 0.304 | 0.304 | 4.11 | 5.76 | 0.6573 | 2.77 | 4.31 | 477,493.70 | 4.93 | 0.7238 | 5.42 | 0.8212 | 45.26 | 46.94 | 7.50 | 1.13 | 10.49 | -- | 0.0017 | 0.00 | 4.64 | 17.41 | 413.17 | 82.20 | 10.18 | -- |
| Candel Therapeutics Inc | 0.00 | -37.37m | 364.97m | 42.00 | -- | 60.23 | -- | -- | -1.29 | -1.29 | 0.00 | 0.2037 | 0.00 | -- | -- | 0.00 | -75.90 | -- | -93.79 | -- | -- | -- | -- | -- | -- | -38.49 | 0.7674 | -- | -100.00 | -- | -101.87 | -- | -- | -- |
| Shattuck Labs Inc | 2.72m | -85.08m | 367.09m | 75.00 | -- | 2.85 | -- | 135.21 | -1.93 | -1.93 | 0.0608 | 2.71 | 0.0168 | -- | -- | 36,200.00 | -52.52 | -29.14 | -57.94 | -32.42 | -- | -- | -3,133.63 | -565.33 | -- | -- | 0.00 | -- | 154.14 | -40.62 | 14.37 | -- | -19.15 | -- |
| Organogenesis Holdings Inc | 435.47m | 5.82m | 367.23m | 862.00 | 63.71 | 1.32 | 17.30 | 0.8433 | 0.0435 | 0.0435 | 3.28 | 2.11 | 0.9628 | 4.08 | 4.63 | 505,190.30 | 1.29 | 5.46 | 1.56 | 6.90 | 75.07 | 74.94 | 1.34 | 4.81 | 2.41 | 8.78 | 0.1955 | 0.00 | -3.94 | 17.49 | -68.16 | -- | 67.34 | -- |
| Anavex Life Sciences Corp | 0.00 | -40.59m | 368.19m | 40.00 | -- | 2.70 | -- | -- | -0.4962 | -0.4962 | 0.00 | 1.61 | 0.00 | -- | -- | 0.00 | -26.73 | -40.04 | -28.98 | -43.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 0.9857 | -- | -- | -- |
| Amarin Corporation plc (ADR) | 277.46m | -52.61m | 368.38m | 275.00 | -- | 0.6746 | -- | 1.33 | -0.1288 | -0.1288 | 0.679 | 1.33 | 0.3363 | 0.4197 | 2.23 | 1,008,927.00 | -6.38 | -4.48 | -8.90 | -6.54 | 63.61 | 75.70 | -18.96 | -8.59 | 1.93 | -- | 0.00 | -- | -16.87 | 6.01 | 44.13 | -- | 55.83 | -- |
Data as of May 23 2024. Currency figures normalised to ADC Therapeutics SA's reporting currency: US Dollar USD
42.93%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Redmile Group LLCas of 31 Mar 2024 | 15.27m | 18.44% |
| Prosight Management LPas of 31 Mar 2024 | 7.05m | 8.51% |
| Oaktree Capital Management LPas of 25 Apr 2024 | 4.02m | 4.85% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 2.69m | 3.25% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 1.54m | 1.86% |
| Bank of America, NA (Private Banking)as of 31 Mar 2024 | 1.18m | 1.43% |
| Millennium Management LLCas of 31 Mar 2024 | 1.01m | 1.22% |
| Adage Capital Management LPas of 31 Mar 2024 | 1.00m | 1.21% |
| Citadel Advisors LLCas of 31 Mar 2024 | 942.51k | 1.14% |
| Vantage Consulting Group, Inc.as of 31 Mar 2024 | 850.74k | 1.03% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
